On 21 March 2025, VISEN Pharmaceuticals (2561.HK) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx). The IPO recorded oversubscription of 72.64 times with positive market responses. After the full exercise of the Offer Size Adjustment Option, the total amount of fund raised was approximately HKD 783 million. CBI is honored to participate in the due diligence work for this IPO Project.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China founded in November 2018. The company has one core product and two other pipeline drug candidates.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management and shareholders, and provided various information including litigation records, bankruptcy and winding-up records, media search and related companies. The due diligence project globally covered 7 countries and regions, including China, Hong Kong, the United States, New Zealand and Singapore.